Sinclair is a Managing Partner at Epidarex Capital, an international life science and health technology venture fund based in Edinburgh, UK and Bethesda, Maryland in the US. Sinclair currently serves on the Board of Directors of Apellis Pharmaceuticals Inc., Clyde Biosciences Ltd., Edinburgh Molecular Imaging Ltd., Maxcyte Inc., and Sirakoss Ltd. He holds an M.B.A. from Columbia Business School, an M.A. (Hons.) in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. Sinclair is a former St. Andrew’s Society of New York Scholar and an RC Kopf Fellow in international business at Columbia University.